telehealth.helpFind my match

Home WikiTelehealth Pharmacy & compounding

Compounded tirzepatide

From WikiTelehealth, the telehealth.help reference · Last updated

Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy for an individual prescription, rather than made by the brand manufacturer. It is not an FDA-approved product and is separate from the approved brands Mounjaro and Zepbound.

Compounded tirzepatide
Active ingredientTirzepatide
Prepared byState-licensed compounding pharmacy
FDA-approvedNo
Common formWeekly injection (vial)
Shortage resolvedDecember 19, 2024 (reaffirmed)
Approved brandsMounjaro, Zepbound

Background

Tirzepatide is a dual GIP and GLP-1 receptor agonist. The FDA approved it as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023. Compounded tirzepatide uses the same molecule but is prepared by a compounding pharmacy, usually as a weekly injection in vials.

Shortage history

Tirzepatide injection products were added to the FDA drug shortage list in December 2022. During the shortage, compounders were allowed to make copies, and many online programs began offering compounded tirzepatide.

The FDA first found the tirzepatide shortage resolved on October 2, 2024. After a lawsuit, the decision was sent back for review, and on December 19, 2024 the FDA again found the shortage resolved. It gave 503A pharmacies until February 18, 2025 and 503B outsourcing facilities until March 19, 2025. A court denied a request to block the decision on March 5, 2025.

Availability after the shortage

After the shortage ended, compounded tirzepatide remains available through 503A pharmacies when a prescriber orders a version for an individual patient. A 503A pharmacy may not regularly make a product that is essentially a copy of Mounjaro or Zepbound. Prescriptions often call for a strength the manufacturer does not sell or an added ingredient. In its April 1, 2026 update, the FDA said tirzepatide was not on the 503B bulks list, so outsourcing facilities generally cannot compound it from bulk ingredients.

Comparison with brand-name tirzepatide

Brand-name tirzepatide is sold in single-dose pens and vials with an FDA-approved label, in doses from 2.5 mg to 15 mg. Compounded tirzepatide is not FDA-approved, is labeled by the pharmacy and is made for one patient, so strength and form can differ from the brand. Online programs that offer compounded or brand tirzepatide are compared on the compounded tirzepatide page.

Timeline

  1. December 2022Tirzepatide injection added to the FDA drug shortage list.
  2. October 2, 2024FDA first finds the shortage resolved.
  3. December 19, 2024FDA reaffirms the shortage is resolved after review.
  4. February 18, 2025End of 503A shortage-based compounding.
  5. March 19, 2025End of 503B shortage-based compounding.

Compare compounded tirzepatide programs

See also

References

  1. FDA: Resolution of tirzepatide injection product shortage (December 19, 2024). fda.gov
  2. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). fda.gov
  3. FDA: Human drug compounding laws. fda.gov

Last updated . Category: Pharmacy & compounding. Browse all 38 WikiTelehealth entries.